Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.70) by 1.43 percent. This is a 31 percent increase over losses of $(1.00) per share from the same period last year.